LRMR Larimar Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LRMR

Price (delayed)

$7.765

Market cap

$495.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.84

Enterprise value

$472.87M

Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical ...

Highlights
The EPS has decreased by 40% from the previous quarter but it has increased by 39% YoY
LRMR's quick ratio is down by 37% since the previous quarter and by 17% year-on-year
LRMR's equity is down by 26% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://larimartx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of LRMR
Market
Shares outstanding
63.8M
Market cap
$495.41M
Enterprise value
$472.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.17
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$36.95M
EBITDA
-$36.64M
Free cash flow
-$33.62M
Per share
EPS
-$0.84
Free cash flow per share
-$0.77
Book value per share
$1.86
Revenue per share
$0
TBVPS
$2.19
Balance sheet
Total assets
$95.94M
Total liabilities
$14.22M
Debt
$5.55M
Equity
$81.72M
Working capital
$80.67M
Liquidity
Debt to equity
0.07
Current ratio
9.49
Quick ratio
9.27
Net debt/EBITDA
0.62
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.3%
Return on equity
-38.8%
Return on invested capital
-102.8%
Return on capital employed
-42.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LRMR stock price

How has the Larimar Therapeutics stock price performed over time
Intraday
2.04%
1 week
20.57%
1 month
0.58%
1 year
68.8%
YTD
70.66%
QTD
2.31%

Financial performance

How have Larimar Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$41.76M
Net income
-$36.95M
Gross margin
N/A
Net margin
N/A
Larimar Therapeutics's operating income has decreased by 14% YoY and by 10% QoQ
The company's net income fell by 11% QoQ and by 4.5% YoY

Growth

What is Larimar Therapeutics's growth rate over time

Valuation

What is Larimar Therapeutics stock price valuation
P/E
N/A
P/B
4.17
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 40% from the previous quarter but it has increased by 39% YoY
LRMR's P/B is 145% above its 5-year quarterly average of 1.7 and 119% above its last 4 quarters average of 1.9
LRMR's equity is down by 26% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Larimar Therapeutics business performance
The ROIC has contracted by 33% from the previous quarter and by 30% YoY
LRMR's ROE is down by 19% since the previous quarter but it is up by 8% year-on-year
Larimar Therapeutics's ROA has decreased by 18% from the previous quarter but it has increased by 4.5% YoY

Dividends

What is LRMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LRMR.

Financial health

How did Larimar Therapeutics financials performed over time
The current ratio has declined by 37% since the previous quarter and by 16% year-on-year
LRMR's quick ratio is down by 37% since the previous quarter and by 17% year-on-year
The debt is 93% less than the equity
LRMR's debt to equity is up by 40% YoY and by 17% from the previous quarter
LRMR's equity is down by 26% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.